Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews

01-04-2024 | Metastasis | Review

The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets

Authors: Yan Xu, Zhipeng Gao, Xiaoyu Sun, Jun Li, Toshinori Ozaki, Du Shi, Meng Yu, Yuyan Zhu

Published in: Cancer and Metastasis Reviews

Login to get access

Abstract

Metastasis is a major contributor to treatment failure and death in urological cancers, representing an important biomedical challenge at present. Metastases form as a result of cancer cells leaving the primary site, entering the vasculature and lymphatic vessels, and colonizing clones elsewhere in the body. However, the specific regulatory mechanisms of action underlying the metastatic process of urological cancers remain incompletely elucidated. With the deepening of research, circular RNAs (circRNAs) have been found to not only play a significant role in tumor progression and prognosis but also show aberrant expression in various tumor metastases, consequently impacting tumor metastasis through multiple pathways. Therefore, circRNAs are emerging as potential tumor markers and treatment targets. This review summarizes the research progress on elucidating how circRNAs regulate the urological cancer invasion-metastasis cascade response and related processes, as well as their role in immune microenvironment remodeling and circRNA vaccines. This body of work highlights circRNA regulation as an emerging therapeutic target for urological cancers, which should motivate further specific research in this regard.
Literature
1.
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: a Cancer Journal for Clinicians, 73(1), 17–48.PubMed
2.
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., et al. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: a Cancer Journal for Clinicians, 67(2), 93–99.PubMed
3.
Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell., 147(2), 275–292.PubMedCrossRef
4.
Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., & Kjems, J. (2019). The biogenesis, biology and characterization of circular RNAs. Nature Reviews Genetics, 20(11), 675–691.PubMedCrossRef
5.
Pisignano, G., Michael, D. C., Visal, T. H., Pirlog, R., Ladomery, M., & Calin, G. A. (2023). Going circular: history, present, and future of circRNAs in cancer. Oncogene, 42.
6.
Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J., & Kleinschmidt, A. K. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proceedings of the National Academy of Sciences of the United States of America, 73(11), 3852–3856.PubMedCrossRef
7.
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature., 495(7441), 333–338.PubMedCrossRef
8.
Li, X., Ding, J., Wang, X., Cheng, Z., & Zhu, Q. (2020). NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma. Oncogene., 39(4), 891–904.PubMedCrossRef
9.
Zeng, Z., Xia, L., Fan, S., Zheng, J., Qin, J., Fan, X., et al. (2021). Circular RNA CircMAP3K5 acts as a microRNA-22-3p sponge to promote resolution of intimal hyperplasia Via TET2-mediated smooth muscle cell differentiation. Circulation., 143(4), 354–371.PubMedCrossRef
10.
van Zonneveld, A. J., Kölling, M., Bijkerk, R., & Lorenzen, J. M. (2021). Circular RNAs in kidney disease and cancer. Nature Reviews Nephrology, 17(12), 814–826.PubMedCrossRef
11.
Zhou, Z., Sun, B., Huang, S., & Zhao, L. (2019). Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death & Disease, 10(7), 503.CrossRef
12.
Wang, Y., Zhang, Y., Wang, P., Fu, X., & Lin, W. (2020). Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Molecular Cancer, 19(1), 149.PubMedPubMedCentralCrossRef
13.
Yang, X., Ye, T., Liu, H., Lv, P., Duan, C., Wu, X., et al. (2021). Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Molecular Cancer, 20(1), 4.PubMedCrossRef
14.
Hua, J. T., Chen, S., & He, H. H. (2019). Landscape of noncoding RNA in prostate cancer. Trends in Genetics : TIG, 35(11), 840–851.PubMedCrossRef
15.
Goodall, G. J., & Wickramasinghe, V. O. (2021). RNA in cancer. Nature Reviews Cancer, 21(1), 22–36.PubMedCrossRef
16.
Li, X., Yang, L., & Chen, L. L. (2018). The biogenesis, functions, and challenges of circular RNAs. Molecular Cell, 71(3), 428–442.PubMedCrossRef
17.
Zhang, Y., Zhang, X. O., Chen, T., Xiang, J. F., Yin, Q. F., Xing, Y. H., et al. (2013). Circular intronic long noncoding RNAs. Molecular Cell, 51(6), 792–806.PubMedCrossRef
18.
Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., et al. (2017). Corrigendum: Exon-intron circular RNAs regulate transcription in the nucleus. Nature Structural & Molecular Biology, 24(2), 194.CrossRef
19.
Lu, Z., Filonov, G. S., Noto, J. J., Schmidt, C. A., Hatkevich, T. L., Wen, Y., et al. (2015). Metazoan tRNA introns generate stable circular RNAs in vivo. RNA (New York, NY)., 21(9), 1554–1565.CrossRef
20.
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., et al. (2013). Natural RNA circles function as efficient microRNA sponges. Nature, 495(7441), 384–388.PubMedCrossRef
21.
Okholm, T. L. H., Sathe, S., Park, S. S., Kamstrup, A. B., Rasmussen, A. M., Shankar, A., et al. (2020). Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression. Genome Medicine, 12(1), 112.PubMedPubMedCentralCrossRef
22.
Xie, F., Xiao, X., Tao, D., Huang, C., Wang, L., Liu, F., et al. (2020). circNR3C1 suppresses bladder cancer progression through acting as an endogenous blocker of BRD4/C-myc complex. Molecular Therapy--Nucleic Acids, 22, 510–519.PubMedPubMedCentralCrossRef
23.
Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., et al. (2015). Exon-intron circular RNAs regulate transcription in the nucleus. Nature Structural & Molecular Biology, 22(3), 256–264.CrossRef
24.
Chen, C. Y., & Sarnow, P. (1995). Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science (New York, N.Y.), 268(5209), 415–417.PubMedCrossRef
25.
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020). Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 19(11), 776–800.PubMedCrossRef
26.
Weigel, C., Veldwijk, M. R., Oakes, C. C., Seibold, P., Slynko, A., Liesenfeld, D. B., et al. (2016). Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis. Nature Communications, 7, 10893.PubMedPubMedCentralCrossRef
27.
Pietri, E., Conteduca, V., Andreis, D., Massa, I., Melegari, E., Sarti, S., et al. (2016). Androgen receptor signaling pathways as a target for breast cancer treatment. Endocrine-Related Cancer, 23(10), R485–R498.PubMedCrossRef
28.
Yin, J., Liu, Y. N., Tillman, H., Barrett, B., Hewitt, S., Ylaya, K., et al. (2014). AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Research, 74(16), 4306–4317.PubMedPubMedCentralCrossRef
29.
Yang, L., Huang, W., Bai, X., Wang, H., Wang, X., Xiao, H., et al. (2023). Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling. Cell Death & Disease, 14(6), 363.CrossRef
30.
Deng, G., Wang, R., Sun, Y., Huang, C. P., Yeh, S., You, B., et al. (2021). Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Cell Death and Differentiation, 28(7), 2145–2159.PubMedPubMedCentralCrossRef
31.
Chen, J., Sun, Y., Ou, Z., Yeh, S., Huang, C. P., You, B., et al. (2020). Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion. EMBO Reports, 21(4), e48467.PubMedPubMedCentralCrossRef
32.
Yang, Z., Qu, C. B., Zhang, Y., Zhang, W. F., Wang, D. D., Gao, C. C., et al. (2019). Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene, 38(14), 2516–2532.PubMedCrossRef
33.
34.
Chen, W., Cen, S., Zhou, X., Yang, T., Wu, K., Zou, L., et al. (2020). Circular RNA CircNOLC1, upregulated by NF-KappaB, promotes the progression of prostate cancer via miR-647/PAQR4 Axis. Frontiers in Cell and Development Biology, 8, 624764.CrossRef
35.
Han, Z., Zhang, Y., Sun, Y., Chen, J., Chang, C., Wang, X., et al. (2018). ERβ-mediated alteration of circATP2B1 and miR-204-3p signaling promotes invasion of clear cell renal cell carcinoma. Cancer Research, 78(10), 2550–2563.PubMedCrossRef
36.
Gupta, G. P., & Massagué, J. (2006). Cancer metastasis: building a framework. Cell., 127(4), 679–695.PubMedCrossRef
37.
38.
Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020). EMT, MET, plasticity, and tumor metastasis. Trends in Cell Biology, 30(10), 764–776.PubMedPubMedCentralCrossRef
39.
Pastushenko, I., & Blanpain, C. (2019). EMT transition states during tumor progression and metastasis. Trends in Cell Biology, 29(3), 212–226.PubMedCrossRef
40.
Stuelten, C. H., Parent, C. A., & Montell, D. J. (2018). Cell motility in cancer invasion and metastasis: insights from simple model organisms. Nature Reviews Cancer, 18(5), 296–312.PubMedPubMedCentralCrossRef
41.
Slattum, G. M., & Rosenblatt, J. (2014). Tumour cell invasion: An emerging role for basal epithelial cell extrusion. Nature Reviews Cancer, 14(7), 495–501.PubMedPubMedCentralCrossRef
42.
Li, W., Yang, F. Q., Sun, C. M., Huang, J. H., Zhang, H. M., Li, X., et al. (2020). circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma. Theranostics, 10(10), 4395–4409.PubMedPubMedCentralCrossRef
43.
Nielsen, J., Kristensen, M. A., Willemoës, M., Nielsen, F. C., & Christiansen, J. (2004). Sequential dimerization of human zipcode-binding protein IMP1 on RNA: A cooperative mechanism providing RNP stability. Nucleic Acids Research, 32(14), 4368–4376.PubMedPubMedCentralCrossRef
44.
Xie, F., Huang, C., Liu, F., Zhang, H., Xiao, X., Sun, J., et al. (2021). CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression. Molecular Cancer, 20(1), 68.PubMedPubMedCentralCrossRef
45.
Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., et al. (2017). Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Research, 27(5), 626–641.PubMedPubMedCentralCrossRef
46.
Meyer, K. D., Patil, D. P., Zhou, J., Zinoviev, A., Skabkin, M. A., Elemento, O., et al. (2015). 5’ UTR m(6)A promotes Cap-independent translation. Cell, 163(4), 999–1010.PubMedPubMedCentralCrossRef
47.
Wang, Y., Liu, J., Ma, J., Sun, T., Zhou, Q., Wang, W., et al. (2019). Exosomal circRNAs: Biogenesis, effect and application in human diseases. Molecular Cancer, 18(1), 116.PubMedPubMedCentralCrossRef
48.
Chen, X., Chen, R. X., Wei, W. S., Li, Y. H., Feng, Z. H., Tan, L., et al. (2018). PRMT5 circular RNA promotes metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce epithelial-mesenchymal transition. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(24), 6319–6330.PubMedCrossRef
49.
Yang, C., Wu, S., Mou, Z., Zhou, Q., Dai, X., Ou, Y., et al. (2022). Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments. Molecular Therapy : The Journal of the American Society of Gene Therapy, 30(3), 1054–1070.PubMedCrossRef
50.
Tang, Y., Liu, J., Li, X., & Wang, W. (2021). Exosomal circRNA HIPK3 knockdown inhibited cell proliferation and metastasis in prostate cancer by regulating miR-212/BMI-1 pathway. Journal of Biosciences, 46.
51.
Ding, L., Zheng, Q., Lin, Y., Wang, R., Wang, H., Luo, W., et al. (2023). Exosome-derived circTFDP2 promotes prostate cancer progression by preventing PARP1 from caspase-3-dependent cleavage. Clinical and Translational Medicine, 13(1), e1156.PubMedPubMedCentralCrossRef
52.
Cen, J., Liang, Y., Huang, Y., Pan, Y., Shu, G., Zheng, Z., et al. (2021). Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Molecular Cancer, 20(1), 19.PubMedPubMedCentralCrossRef
53.
Lu, Q., Liu, T., Feng, H., Yang, R., Zhao, X., Chen, W., et al. (2019). Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Molecular Cancer, 18(1), 111.PubMedPubMedCentralCrossRef
54.
Chao, F., Song, Z., Wang, S., Ma, Z., Zhuo, Z., Meng, T., et al. (2021). Novel circular RNA circSOBP governs amoeboid migration through the regulation of the miR-141-3p/MYPT1/p-MLC2 axis in prostate cancer. Clinical and Translational Medicine, 11(3), e360.PubMedPubMedCentralCrossRef
55.
Shen, Z., Zhou, L., Zhang, C., & Xu, J. (2020). Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Letters, 468, 88–101.PubMedCrossRef
56.
Yang, C., Yuan, W., Yang, X., Li, P., Wang, J., Han, J., et al. (2018). Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Molecular Cancer, 17(1), 19.PubMedPubMedCentralCrossRef
57.
Dong, W., Bi, J., Liu, H., Yan, D., He, Q., Zhou, Q., et al. (2019). Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis. Molecular Cancer, 18(1), 95.PubMedPubMedCentralCrossRef
58.
Zhang, X., Liu, X., Jing, Z., Bi, J., Li, Z., Liu, X., et al. (2020). The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer Gene Therapy, 27(3–4), 189–202.PubMedCrossRef
59.
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., et al. (2014). Adrenocortical carcinoma. Endocrine Reviews, 35(2), 282–326.PubMedCrossRef
60.
Li, W., Liu, R., Wei, D., Zhang, W., Zhang, H., Huang, W., et al. (2020). Circular RNA circ-CCAC1 facilitates adrenocortical carcinoma cell proliferation, migration, and invasion through regulating the miR-514a-5p/C22orf46 axis. BioMed Research International, 2020, 3501451.PubMedPubMedCentral
61.
Hakenberg, O. W., Dräger, D. L., Erbersdobler, A., Naumann, C. M., Jünemann, K. P., & Protzel, C. (2018). The diagnosis and treatment of penile cancer. Deutsches Ärzteblatt International, 115(39), 646–652.PubMed
62.
Heideman, D. A., Waterboer, T., Pawlita, M., Delis-van Diemen, P., Nindl, I., Leijte, J. A., et al. (2007). Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25(29), 4550–4556.PubMedCrossRef
63.
Bonelli, P., Borrelli, A., Tuccillo, F. M., Buonaguro, F. M., & Tornesello, M. L. (2021). The Role of circRNAs in Human Papillomavirus (HPV)-Associated Cancers. Cancers, 13(5).
64.
Bockhorn, M., Jain, R. K., & Munn, L. L. (2007). Active versus passive mechanisms in metastasis: Do cancer cells crawl into vessels, or are they pushed? The Lancet Oncology, 8(5), 444–448.PubMedPubMedCentralCrossRef
65.
Lin, Y., Xu, J., & Lan, H. (2019). Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. Journal of Hematology & Oncology, 12(1), 76.CrossRef
66.
Dua, R. S., Gui, G. P., & Isacke, C. M. (2005). Endothelial adhesion molecules in breast cancer invasion into the vascular and lymphatic systems. European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 31(8), 824–832.PubMedCrossRef
67.
Follain, G., Herrmann, D., Harlepp, S., Hyenne, V., Osmani, N., Warren, S. C., et al. (2020). Fluids and their mechanics in tumour transit: shaping metastasis. Nature Reviews Cancer, 20(2), 107–124.PubMedCrossRef
68.
Cheng, X., & Cheng, K. (2021). Visualizing cancer extravasation: from mechanistic studies to drug development. Cancer Metastasis Reviews, 40(1), 71–88.PubMedCrossRef
69.
Weis, S., Cui, J., Barnes, L., & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223–229.PubMedPubMedCentralCrossRef
70.
Dufies, M., Giuliano, S., Ambrosetti, D., Claren, A., Ndiaye, P. D., Mastri, M., et al. (2017). Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Research, 77(5), 1212–1226.PubMedCrossRef
71.
Ndiaye, P. D., Dufies, M., Giuliano, S., Douguet, L., Grépin, R., Durivault, J., et al. (2019). VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics, 9(3), 661–675.PubMedCrossRef
72.
Nisato, R. E., Tille, J. C., & Pepper, M. S. (2003). Lymphangiogenesis and tumor metastasis. Thrombosis and Haemostasis, 90(4), 591–597.PubMedCrossRef
73.
Zhong, Z., Huang, M., Lv, M., He, Y., Duan, C., Zhang, L., et al. (2017). Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Letters, 403, 305–317.PubMedCrossRef
74.
Dai, Y., Li, D., Chen, X., Tan, X., Gu, J., Chen, M., et al. (2018). Circular RNA myosin light chain kinase (MYLK) promotes prostate cancer progression through modulating Mir-29a expression. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 24, 3462–3471.PubMedCrossRef
75.
Li, J., Huang, C., Zou, Y., Yu, J., & Gui, Y. (2020). Circular RNA MYLK promotes tumour growth and metastasis via modulating miR-513a-5p/VEGFC signalling in renal cell carcinoma. Journal of Cellular and Molecular Medicine, 24(12), 6609–6621.PubMedCrossRef
76.
Miles, F. L., Pruitt, F. L., van Golen, K. L., & Cooper, C. R. (2008). Stepping out of the flow: capillary extravasation in cancer metastasis. Clinical & Experimental Metastasis, 25(4), 305–324.CrossRef
77.
Sadik, C. D., Kim, N. D., & Luster, A. D. (2011). Neutrophils cascading their way to inflammation. Trends in Immunology, 32(10), 452–460.PubMedCrossRef
78.
García-Román, J., & Zentella-Dehesa, A. (2013). Vascular permeability changes involved in tumor metastasis. Cancer Letters, 335(2), 259–269.PubMedCrossRef
79.
Sawant Dessai, A., Dominguez, M. P., Chen, U. I., Hasper, J., Prechtl, C., Yu, C., et al. (2021). Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone. Cancer Research, 81(1), 50–63.PubMed
80.
Gilardi, M., Bersini, S., Valtorta, S., Proietto, M., Crippa, M., Boussommier-Calleja, A., et al. (2021). The driving role of the Cdk5/Tln1/FAK(S732) axis in cancer cell extravasation dissected by human vascularized microfluidic models. Biomaterials, 276, 120975.PubMedCrossRef
81.
Liu, H., Bi, J., Dong, W., Yang, M., Shi, J., Jiang, N., et al. (2018). Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. Molecular Cancer, 17(1), 161.PubMedCrossRef
82.
Cruz-Munoz, W., Sanchez, O. H., Di Grappa, M., English, J. L., Hill, R. P., & Khokha, R. (2006). Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice. Oncogene, 25(49), 6489–6496.PubMedCrossRef
83.
Xie, X., Sun, F. K., Huang, X., Wang, C. H., Dai, J., Zhao, J. P., et al. (2021). A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis. Aging, 13(15), 19908–19919.PubMedCrossRef
84.
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572.PubMedCrossRef
85.
Hart, I. R., & Fidler, I. J. (1980). Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Research, 40(7), 2281–2287.PubMed
86.
Turajlic, S., & Swanton, C. (2016). Metastasis as an evolutionary process. Science (New York, N.Y.), 352(6282), 169–175.PubMedCrossRef
87.
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014). From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell, 25(3), 318–334.PubMedCrossRef
88.
Wieland, E., Rodriguez-Vita, J., Liebler, S. S., Mogler, C., Moll, I., Herberich, S. E., et al. (2017). Endothelial Notch1 Activity Facilitates Metastasis. Cancer Cell, 31(3), 355–367.PubMedCrossRef
89.
Huang, Z., Ding, Y., Zhang, L., He, S., Jia, Z., Gu, C., et al. (2020). Upregulated circPDK1 promotes RCC cell migration and invasion by regulating the miR-377-3P-NOTCH1 axis in renal cell carcinoma. OncoTargets and Therapy, 13, 11237–11252.PubMedCrossRef
90.
Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, E. D. (2006). Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Research, 66(23), 11271–11278.PubMedCrossRef
91.
Yang, C., Wu, S., Wu, X., Zhou, X., Jin, S., & Jiang, H. (2019). Silencing circular RNA UVRAG inhibits bladder cancer growth and metastasis by targeting the microRNA-223/fibroblast growth factor receptor 2 axis. Cancer Science, 110(1), 99–106.PubMedCrossRef
92.
Li, L., Ameri, A. H., Wang, S., Jansson, K. H., Casey, O. M., Yang, Q., et al. (2019). EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene, 38(35), 6241–6255.PubMedPubMedCentralCrossRef
93.
Lu, J., Zhong, C., Luo, J., Shu, F., Lv, D., Liu, Z., et al. (2021). HnRNP-L-regulated circCSPP1/miR-520h/EGR1 axis modulates autophagy and promotes progression in prostate cancer. Molecular Therapy--Nucleic Acids, 26, 927–944.PubMedPubMedCentralCrossRef
94.
Xiao, Y., & Yu, D. (2021). Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics, 221, 107753.CrossRef
95.
96.
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021). Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduction and Targeted Therapy, 6(1), 75.PubMedPubMedCentralCrossRef
97.
Huang, X., Wang, J., Guan, J., Zheng, Z., Hao, J., Sheng, Z., et al. (2022). Exosomal Circsafb2 reshaping tumor environment to promote renal cell carcinoma progression by mediating M2 macrophage polarization. Frontiers in Oncology, 12, 808888.PubMedPubMedCentralCrossRef
98.
Du, C., Yan, Q., Wang, Y., Ren, L., Lu, H., Han, M., et al. (2023). Circular RNA AGAP1 stimulates immune escape and distant metastasis in renal cell carcinoma. Molecular Biotechnology, 66.
99.
Lv, J., Li, K., Yu, H., Han, J., Zhuang, J., Yu, R., et al. (2023). HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. Journal of experimental & clinical cancer research : CR, 42(1), 41.PubMedCentralCrossRef
100.
Sun, J., Zhang, H., Wei, W., Xiao, X., Huang, C., Wang, L., et al. (2023). Regulation of CD8(+) T cells infiltration and immunotherapy by circMGA/HNRNPL complex in bladder cancer. Oncogene, 42(15), 1247–1262.PubMedCrossRef
101.
Liu, Q., You, B., Meng, J., Huang, C. P., Dong, G., Wang, R., et al. (2022). Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Therapy, 29(12), 1988–2000.PubMedPubMedCentralCrossRef
102.
Meng, M., & Wu, Y. C. (2022). LMX1B activated circular RNA GFRA1 modulates the tumorigenic properties and immune escape of prostate cancer. Journal of Immunology Research, 2022, 7375879.PubMedPubMedCentralCrossRef
103.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews Cancer, 3(6), 453–458.PubMedCrossRef
104.
Liu, Q., Zhang, H., Jiang, X., Qian, C., Liu, Z., & Luo, D. (2017). Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Molecular Cancer, 16(1), 176.PubMedPubMedCentralCrossRef
105.
Brodt, P. (2016). Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 22(24), 5971–5982.PubMedCrossRef
106.
Adekoya, T. O., & Richardson, R. M. (2020). Cytokines and chemokines as mediators of prostate cancer metastasis. International Journal of Molecular Sciences, 21(12).
107.
108.
Bianchi, M., Sun, M., Jeldres, C., Shariat, S. F., Trinh, Q. D., Briganti, A., et al. (2012). Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 23(4), 973–980.PubMedCrossRef
109.
Grünwald, V., Eberhardt, B., Bex, A., Flörcken, A., Gauler, T., Derlin, T., et al. (2018). An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nature Reviews Urology, 15(8), 511–521.PubMedPubMedCentralCrossRef
110.
Chow, W. H., Dong, L. M., & Devesa, S. S. (2010). Epidemiology and risk factors for kidney cancer. Nature Reviews Urology, 7(5), 245–257.PubMedCrossRef
111.
Gong, D., Sun, Y., Guo, C., Sheu, T. J., Zhai, W., Zheng, J., et al. (2021). Androgen receptor decreases renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis. Clinical and Translational Medicine, 11(3), e353.PubMedCrossRef
112.
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., et al. (2019). The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 19(1), 9–31.PubMedCrossRef
113.
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., et al. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 15(1), 35–44.PubMedCrossRef
114.
Liu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., et al. (2016). Tumor exosomal rnas promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell, 30(2), 243–256.PubMedCrossRef
115.
Li, W., Song, Y. Y., Rao, T., Yu, W. M., Ruan, Y., Ning, J. Z., et al. (2022). CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma. Journal of Cellular and Molecular Medicine, 26(6), 1729–1741.PubMedCrossRef
116.
Liu, H., Hu, G., Wang, Z., Liu, Q., Zhang, J., Chen, Y., et al. (2020). circPTCH1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP14 axis. Theranostics, 10(23), 10791–10807.PubMedCrossRef
117.
Lv, Q., Wang, G., Zhang, Y., Shen, A., Tang, J., Sun, Y., et al. (2021). CircAGAP1 promotes tumor progression by sponging miR-15-5p in clear cell renal cell carcinoma. Journal of Experimental & Clinical Cancer Research : CR, 40(1), 76.CrossRef
118.
Liang, Y., Cen, J., Huang, Y., Fang, Y., Wang, Y., Shu, G., et al. (2022). CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug. Molecular Cancer, 21(1), 224.PubMedCrossRef
119.
Zhao, B., Huang, C., Pan, J., Hu, H., Liu, X., Zhang, K., et al. (2022). circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p. Cell Death & Disease, 13(12), 1030.CrossRef
120.
Xie, F., Li, Y., Wang, M., Huang, C., Tao, D., Zheng, F., et al. (2018). Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. Molecular Cancer, 17(1), 144.PubMedCrossRef
121.
Bi, J., Liu, H., Dong, W., Xie, W., He, Q., Cai, Z., et al. (2019). Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence. Molecular Cancer, 18(1), 133.PubMedCrossRef
122.
Zhu, J., Luo, Y., Zhao, Y., Kong, Y., Zheng, H., Li, Y., et al. (2021). circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling. Molecular Therapy : The Journal of the American Society of Gene Therapy, 29(5), 1838–1852.PubMedCrossRef
123.
Su, H., Tao, T., Yang, Z., Kang, X., Zhang, X., Kang, D., et al. (2019). Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Molecular Cancer, 18(1), 27.PubMedCrossRef
124.
Gu, C., Zhou, N., Wang, Z., Li, G., Kou, Y., Yu, S., et al. (2018). circGprc5a promoted bladder oncogenesis and metastasis through Gprc5a-targeting peptide. Molecular Therapy--Nucleic Acids, 13, 633–641.PubMedCrossRef
125.
Li, Y., Kong, Y., An, M., Luo, Y., Zheng, H., Lin, Y., et al. (2023). ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/β-catenin pathway. Journal of Experimental & Clinical Cancer Research : CR, 42(1), 191.CrossRef
126.
Kong, Z., Wan, X., Lu, Y., Zhang, Y., Huang, Y., Xu, Y., et al. (2020). Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. Journal of Cellular and Molecular Medicine, 24(1), 799–813.PubMedCrossRef
127.
Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nature Reviews Cancer, 8(4), 268–278.PubMedCrossRef
128.
Unger, F. T., Witte, I., & David, K. A. (2015). Prediction of individual response to anticancer therapy: historical and future perspectives. Cellular and Molecular Life Sciences: CMLS, 72(4), 729–757.PubMedCrossRef
129.
Ragnarsson, O. (2020). Cushing’s syndrome - Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies. Best Practice & Research. Clinical Endocrinology & Metabolism, 34(2), 101382.CrossRef
130.
Jeck, W. R., Sorrentino, J. A., Wang, K., Slevin, M. K., Burd, C. E., Liu, J., et al. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (New York, NY), 19(2), 141–157.CrossRef
131.
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., et al. (2011). Global quantification of mammalian gene expression control. Nature, 473(7347), 337–342.PubMedCrossRef
132.
Rybak-Wolf, A., Stottmeister, C., Glažar, P., Jens, M., Pino, N., Giusti, S., et al. (2015). Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Molecular Cell, 58(5), 870–885.PubMedCrossRef
133.
Shen, T., Han, M., Wei, G., & Ni, T. (2015). An intriguing RNA species--Perspectives of circularized RNA. Protein & Cell, 6(12), 871–880.CrossRef
134.
Wang, P. L., Bao, Y., Yee, M. C., Barrett, S. P., Hogan, G. J., Olsen, M. N., et al. (2014). Circular RNA is expressed across the eukaryotic tree of life. PLoS One, 9(6), e90859.PubMedPubMedCentralCrossRef
135.
Danan, M., Schwartz, S., Edelheit, S., & Sorek, R. (2012). Transcriptome-wide discovery of circular RNAs in Archaea. Nucleic Acids Research, 40(7), 3131–3142.PubMedCrossRef
136.
Li, Y., Zheng, Q., Bao, C., Li, S., Guo, W., Zhao, J., et al. (2015). Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. Cell Research, 25(8), 981–984.PubMedPubMedCentralCrossRef
137.
Luo, J., Li, Y., Zheng, W., Xie, N., Shi, Y., Long, Z., et al. (2019). Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. Molecular Therapy--Nucleic Acids, 18, 916–926.PubMedPubMedCentralCrossRef
138.
Dahl, M., Husby, S., Eskelund, C. W., Besenbacher, S., Fjelstrup, S., Côme, C., et al. (2022). Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: A study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia, 36(1), 177–188.PubMedCrossRef
139.
Zuo, L., Zhang, L., Zu, J., Wang, Z., Han, B., Chen, B., et al. (2020). Circulating circular RNAs as biomarkers for the diagnosis and prediction of outcomes in acute ischemic stroke. Stroke, 51(1), 319–323.PubMedCrossRef
140.
Wang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., et al. (2020). Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research, 48(D1), D1031-D1d41.PubMed
141.
Williford, J. M., Wu, J., Ren, Y., Archang, M. M., Leong, K. W., & Mao, H. Q. (2014). Recent advances in nanoparticle-mediated siRNA delivery. Annual Review of Biomedical Engineering, 16, 347–370.PubMedCrossRef
142.
Yu, C., Zhang, Y., Wang, N., Wei, W., Cao, K., Zhang, Q., et al. (2022). Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA. Biomaterials Research, 26(1), 6.PubMedCrossRef
143.
Mao, W., Wang, K., Xu, B., Zhang, H., Sun, S., Hu, Q., et al. (2021). ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Molecular Cancer, 20(1), 142.PubMedCrossRef
144.
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nature Protocols, 8(11), 2281–2308.PubMedPubMedCentralCrossRef
145.
Zheng, Q., Bao, C., Guo, W., Li, S., Chen, J., Chen, B., et al. (2016). Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nature Communications, 7, 11215.PubMedPubMedCentralCrossRef
146.
Piwecka, M., Glažar, P., Hernandez-Miranda, L. R., Memczak, S., Wolf, S. A., Rybak-Wolf, A., et al. (2017). Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science (New York, NY), 357(6357).
147.
Huang, S., Li, X., Zheng, H., Si, X., Li, B., Wei, G., et al. (2019). Loss of super-enhancer-regulated circRNA Nfix induces cardiac regeneration after myocardial infarction in adult mice. Circulation, 139(25), 2857–2876.PubMedPubMedCentralCrossRef
148.
Li, S., Li, X., Xue, W., Zhang, L., Yang, L. Z., Cao, S. M., et al. (2021). Screening for functional circular RNAs using the CRISPR-Cas13 system. Nature Methods, 18(1), 51–59.PubMedCrossRef
149.
Bennett, C. F., & Swayze, E. E. (2010). RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology, 50, 259–293.PubMedCrossRef
150.
Wesselhoeft, R. A., Kowalski, P. S., & Anderson, D. G. (2018). Engineering circular RNA for potent and stable translation in eukaryotic cells. Nature Communications, 9(1), 2629.PubMedPubMedCentralCrossRef
151.
Verduci, L., Strano, S., Yarden, Y., & Blandino, G. (2019). The circRNA-microRNA code: Emerging implications for cancer diagnosis and treatment. Molecular Oncology, 13(4), 669–680.PubMedPubMedCentralCrossRef
152.
153.
Wurster, S. E., & Maher, L. J., 3rd. (2008). Selection and characterization of anti-NF-kappaB p65 RNA aptamers. RNA (New York, NY), 14(6), 1037–1047.CrossRef
154.
Filonov, G. S., Moon, J. D., Svensen, N., & Jaffrey, S. R. (2014). Broccoli: Rapid selection of an RNA mimic of green fluorescent protein by fluorescence-based selection and directed evolution. Journal of the American Chemical Society, 136(46), 16299–16308.PubMedPubMedCentralCrossRef
155.
Pfafenrot, C., Schneider, T., Müller, C., Hung, L. H., Schreiner, S., Ziebuhr, J., et al. (2021). Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs. Nucleic Acids Research, 49(21), 12502–12516.PubMedPubMedCentralCrossRef
156.
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., et al. (2022). Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell, 185(10), 1728–44.e16.PubMedPubMedCentralCrossRef
157.
Greene, J., Baird, A. M., Brady, L., Lim, M., Gray, S. G., McDermott, R., et al. (2017). Circular RNAs: Biogenesis, function and role in human diseases. Frontiers in Molecular Biosciences, 4, 38.PubMedPubMedCentralCrossRef
158.
Shim, M. S., & Kwon, Y. J. (2010). Efficient and targeted delivery of siRNA in vivo. The FEBS Journal, 277(23), 4814–4827.PubMedCrossRef
159.
Huang, L., & Liu, Y. (2011). In vivo delivery of RNAi with lipid-based nanoparticles. Annual Review of Biomedical Engineering, 13, 507–530.PubMedCrossRef
160.
Fan, Q., Yang, L., Zhang, X., Peng, X., Wei, S., Su, D., et al. (2018). The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Letters, 414, 107–115.PubMedCrossRef
161.
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012). Nanoparticle delivery of cancer drugs. Annual Review of Medicine, 63, 185–198.PubMedCrossRef
162.
Du, W. W., Fang, L., Yang, W., Wu, N., Awan, F. M., Yang, Z., et al. (2017). Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death and Differentiation, 24(2), 357–370.PubMedCrossRef
163.
Liu, X., Zhang, Y., Zhou, S., Dain, L., Mei, L., & Zhu, G. (2022). Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. Journal of Controlled Release: Official Journal of the Controlled Release Society, 348, 84–94.PubMedCrossRef
164.
Li, H., Peng, K., Yang, K., Ma, W., Qi, S., Yu, X., et al. (2022). Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics, 12(14), 6422–6436.PubMedPubMedCentralCrossRef
Metadata
Title
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets
Authors
Yan Xu
Zhipeng Gao
Xiaoyu Sun
Jun Li
Toshinori Ozaki
Du Shi
Meng Yu
Yuyan Zhu
Publication date
01-04-2024
Publisher
Springer US
Published in
Cancer and Metastasis Reviews
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-024-10182-x
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits